Benitec Biopharma Inc. (BNTC)
NasdaqCM · USD · Healthcare · Biotechnology
$8.75 (+1.89%) as of
Key statistics
- Market cap
- 305.35M
- Forward P/E
- -0.93
- EPS (TTM)
- -0.98
- Dividend yield
- 0.00%
- 52-week range
- 8.00 – 16.68
- Beta
- 0.25
- Profit margin
- 0.00%
- Analyst target
- $22.86
- Volume
- 38.04k
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Hayward, CA, United States
- Employees
- 24
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.